Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Nutr Metab Cardiovasc Dis. 2011 May 12;23(1):38–45. doi: 10.1016/j.numecd.2011.02.004

Table 4.

Markers of preclinical cardiovascular disease in different diagnosis of MetS. Comparison is adjusted for age, sex, and race.

No-MetS (n=1775 ) HD (n=328) DD (n=512)
LV mass index (g/m2.7) 36.8±10.6 41.3±9.8* 41.9±10.5*
Prevalence of LVH (%) 13% 22%* 24%*
Relative wall thickness 0.32±0.05 0.34±0.05* 0.34±0.06*
LV dimension index (cm/m) 3.01±0.25 3.06±0.26* 3.07±0.27*
LA dimension index (cm/m) 1.96±0.29 2.08±0.29* 2.10±0.27*
Ejection fraction (%) 64.3±11.2 65.2±12.7 65.3±11.3
Midwall shortening (%) 18.0±2.0 17.6±2.0* 17.6±2.0*
LA systolic force (kdynes) 9.2±4.4 12.4±4.6* 13.1±5.9*
*

p<0.05 vs. No MetS;

†

p<0.05 vs. DD.

DD=diagnosis of MetS based on direct measurements of the components.

HD=diagnosis of MetS based on historical exposition, with one or more treated components of the MetS normal at the time of survey.